Compare Summit Therapeutics Inc (SMMT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs BIO-TECHNE Corp — how do they compare? Summit Therapeutics Inc trades at $17.51 (market cap $13.98B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.33B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TECH | |
|---|---|---|
Market Cap | $13.98B | $11.33B |
Sector | Health | Health |
52-Week High | $26.38 | $72.48 |
52-Week Low | $12.43 | $43.31 |
Enterprise Value | $13.31B | $11.35B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while P/B stands at 22.19. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancer, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.18 suggesting 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish with 61% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on a single drug candidate.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with neutral technical signals and mixed earnings performance. The company reported Q4 2026 revenue of $321.2 million, beating estimates, but net income margins have declined from 25.09% in 2023 to 14.96% in 2026. Key developments include a pending acquisition by Merck KGaA at $73.00 per share and a quarterly dividend of $0.08. Analyst consensus is split with 46% buy and 54% hold ratings.
The stock offers moderate upside to the acquisition price, supported by solid cash flow and institutional interest, but faces risks from margin compression and ongoing shareholder investigations. Valuation multiples like P/E of 62.28 suggest premium pricing, requiring careful assessment of growth sustainability amid competitive and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
